The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance

Diabetes

Volumn 50, Issue 6, 2001, Pages 1378-1388

  Caron, M ^a   Auclair, M ^a   Vigouroux, C ^a   Glorian, M ^a   Forest, C ^a   Capeau, J ^a  

^a INSERM   (France)

Author keywords

ER, endoplasmic reticulum; ERK2, extracellular signal regulated kinase 2; FCS, fetal calf serum; FITC, fluorescein isothyiocyanate; HAART, highly active antiretroviral therapy; IR, insulin receptor; IRS, IR substrate; MAPK, mitogen activated protein kinase; NCS, newborn calf serum; PBS, phosphate buffered saline; PI, protease inhibitor; PPAR , peroxisome proliferator activated receptor ; RXR, retinoid X receptor; SREBP 1, sterol regulatory element binding protein 1

Indexed keywords

AMPRENAVIR; INDINAVIR; INSULIN; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEINASE INHIBITOR; ROSIGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; CORRELATION FUNCTION; ELECTROPHORETIC MOBILITY; ENZYME ACTIVATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPODYSTROPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

EID: 0034987343     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.50.6.1378     Document Type: Article

References (57)

1. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
2. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance
3. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
4. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART)
5. Visceral abdominal-fat accumulation associated with use of indinavir
6. Studies of body composition and fat distribution in HIV-infected and control subjects
7. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
8. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
9. Lipodystrophy in patients naive to HIV protease inhibitors
10. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
11. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
12. Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: The lipodystrophy syndrome
13. Protease inhibitors and adipocyte differentiation in cell culture
14. The mechanism of insulin resistance caused by HIV protease inhibitor therapy
15. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARγ/RXR heterodimer
16. Inhibition of adipocyte differentiation by HIV protease inhibitors
17. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro
18. Syndromes of severe insulin resistance: Clinical and pathophysiological features
19. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety)
20. Lamin A/C gene: Sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy
21. Spontaneous heritable changes leading to increased adipose conversion in 3T3 cells
22. Expression of the phosphoenolpyruvate carboxykinase gene in 3T3-F442A adipose cells: Effects of retinoic acid and differentiation
23. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis
24. Peroxisome proliferator-activated receptor (PPAR) gamma: Adipose-predominant expression and induction early in adipocyte differentiation
25. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor
26. Development of hormone receptors and hormonal responsiveness in vitro: Insulin receptors and insulin sensitivity in the preadipocyte and adipocyte forms of 3T3-L1 cells
27. Alterations in insulin binding accompanying differentiation of 3T3-L1 preadipocytes
28. Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I
29. Regulation of adipose cell number in man
30. Nuclear lamins: Their structure, assembly, and interactions
31. The insulin signalling system and the IRS proteins
32. HIV protease inhibitors
33. Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes
34. Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: Implications for adipocyte differentiation and metabolism
35. Transcriptional control of adipogenesis
36. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
37. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood
38. Sterol regulatory element binding proteins (SREBP)-la and SREBP.2 are linked to the MAP-kinase cascade
39. MAP kinases Erk1/2 phosphorylate sterol regulatory element-binding protein (SREBP)-1a at serine 117 in vitro
40. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
41. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
42. Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans
43. Second-site cleavage in sterol regulatory element-binding protein occurs at transmembrane junction as determined by cysteine panning
44. Nuclear import of sterol regulatory element-binding protein-2, a basic helix-loop-helix-leucine zipper (bHLH-Zip)-containing transcription factor, occurs through the direct interaction of importin beta with HLH-Zip
45. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors
46. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis
47. Peroxisome proliferator and retinoid signaling pathways co-regulate preadipocyte phenotype and survival
48. ADD-1 provides major new insight into the mechanism of insulin action
49. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes
50. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose
51. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism
52. ADD1/SREBP-1c mediates insulin-induced gene expression linked to the MAP kinase pathway
53. Indinavir-associated lipodystrophy
54. Lipodystrophy in HIV-1-infected patients
55. Depot-related gene expression in human subcutaneous and omental adipocytes
56. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation
57. Depot-specific differences in adipose tissue gene expression in lean and obese subjects